Figure 2. Attenuation of rLCMV/INDG Prevents Lethal Disease in Infected Mice.

(A, B) C57BL/6 mice were infected i.v. with 2 × 10⁴ PFU of either rLCMV/INDG or LCMV-ARM. At the indicated time points after inoculation, groups of two or three mice were killed and viral titers in spleen (A) and liver (B) were determined by immunofocus assay. Symbols represent individual mice.

(C) C57BL/6 mice (four per group) were infected with 3 × 10³ PFU rLCMV/INDG or LCMV-ARM i.c. At the time points indicated, they were monitored for clinical signs of choriomeningitis. Animals with terminal disease were killed according to the Swiss law for animal protection.

(D) Mice were infected with 3 × 10³ PFU rLCMV/INDG i.c. Ten days later, NP396-specific CD8⁺ T cells in peripheral blood were enumerated using MHC class I tetramers. Numbers in the upper right quadrants indicate the percentage of NP396-specific CD8⁺ T cells within the total CD8⁺ T cell population. Each panel (A–D) shows the results from one representative experiment of two similar ones.